Olaparib + carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
Phase 2UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Epithelial Cancer
Conditions
Ovarian Epithelial Cancer
Trial Timeline
Aug 1, 2016 → Jul 1, 2023
NCT ID
NCT02822157About Olaparib + carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly
Olaparib + carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly is a phase 2 stage product being developed by AstraZeneca for Ovarian Epithelial Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT02822157. Target conditions include Ovarian Epithelial Cancer.
What happened to similar drugs?
11 of 20 similar drugs in Ovarian Epithelial Cancer were approved
Approved (11) Terminated (4) Active (7)
Hype Score Breakdown
Clinical
12
Activity
4
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02822157 | Phase 2 | UNKNOWN |
Competing Products
20 competing products in Ovarian Epithelial Cancer